Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Chun‐wei Xu"'
Autor:
Chao Zhang, Hua-Fei Chen, Shi Yan, Lin Wu, Li-Xu Yan, Xiao-Long Yan, Dong-Sheng Yue, Chun-Wei Xu, Min Zheng, Ji-Sheng Li, Si-Yang Liu, Ling-Ling Yang, Ben-Yuan Jiang, Qiu-Xiang Ou, Zhen-Bin Qiu, Yang Shao, Yi-Long Wu, Wen-Zhao Zhong
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-9 (2022)
Abstract Despite limited efficacy of immunotherapy for advanced non-small-cell lung cancer (NSCLC) with driver mutations, whether neoadjuvant immunotherapy could be clinically valuable in those patients warrants further investigation. We utilized 40
Externí odkaz:
https://doaj.org/article/b0266695bc4d46cb8301b21ed896e3fd
Autor:
Lei Lei, Wen-xian Wang, Zong-yang Yu, Xian-bin Liang, Wei-wei Pan, Hua-fei Chen, Li-ping Wang, Yong Fang, Min Wang, Chun-wei Xu, Mei-yu Fang
Publikováno v:
Translational Oncology, Vol 13, Iss 2, Pp 329-335 (2020)
BACKGROUND: KRAS gene mutations are well known as a key driver of advanced non–small cell lung cancer (NSCLC). The impact of KRAS-mutant subtypes on the survival benefit from salvage chemotherapy is controversial. Here, we present a real-world stud
Externí odkaz:
https://doaj.org/article/8735d400c9f345c390e3a3ece24e3adf
Autor:
Lei Lei, Wen‐xian Wang, You‐cai Zhu, Jin‐luan Li, Yong Fang, Hong Wang, Wu Zhuang, Yin‐bin Zhang, Li‐ping Wang, Mei‐yu Fang, Chun‐wei Xu, Xiao‐jia Wang, Tang‐feng Lv, Yong Song
Publikováno v:
Cancer Medicine, Vol 9, Iss 1, Pp 12-18 (2020)
Abstract The response to icotinib in advanced non‐small cell lung cancers (NSCLC) with EGFR uncommon mutation (EGFRum) is unclear. Here we reported the efficacy and potential resistance mechanism of icotinib in Chinese EGFRum NSCLC patients. Betwee
Externí odkaz:
https://doaj.org/article/35dceeb41cdd4f86a8452ce1072e9fca
Publikováno v:
Chinese Medical Journal, Vol 132, Iss 24, Pp 3015-3017 (2019)
Externí odkaz:
https://doaj.org/article/18bcef8175fa4babb52c276cf8bcdda9
Autor:
You-cai Zhu, Wen-xian Wang, Chun-wei Xu, Wu Zhuang, Zheng-bo Song, Kai-qi Du, Gang Chen, Tang-feng Lv, Yong Song
Publikováno v:
Cancer Biology & Therapy, Vol 19, Iss 12, Pp 1097-1101 (2018)
In non-small cell lung cancer (NSCLC), driver gene alterations, such as EGFR, ALK, MET, and ROS1, are usually mutually exclusive. Few clinical cases with co-existing ROS1 fusion and de-novo MET amplification have been reported. In addition, the effic
Externí odkaz:
https://doaj.org/article/9b7ae0f932f24e0aa83d261b00db2d57
Autor:
Xue-wen Liu, Xin-ru Chen, Yu-ming Rong, Ning Lyu, Chun-wei Xu, Fang Wang, Wen-yong Sun, San-gao Fang, Jing-ping Yuan, Hui-juan Wang, Wen-xian Wang, Wen-bin Huang, Jian-ping Xu, Zhen-ying Yue, Li-kun Chen
Publikováno v:
Translational Oncology, Vol 13, Iss 12, Pp 100868- (2020)
Background: High frequency of MNNG HOS transforming (MET) exon 14 skipping mutation (MET exon 14Δ) has been reported in pulmonary sarcomatoid carcinomas (PSCs). However, the frequencies differ greatly. Our study aims to investigate the frequency of
Externí odkaz:
https://doaj.org/article/3ad462ee2b0543a3883474de73b4868d
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Salivary duct carcinoma (SDC), an aggressive and rare malignancy with poor prognosis, is mostly associated with the overexpression of the androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2). However, limited data ar
Externí odkaz:
https://doaj.org/article/0a64f7e267184e5d8f2082b37c67e648
Autor:
Chun-wei Xu, Lei Lei, Wen-xian Wang, Li Lin, You-cai Zhu, Hong Wang, Li-yun Miao, Li-ping Wang, Wu Zhuang, Mei-yu Fang, Tang-feng Lv, Yong Song
Publikováno v:
Translational Oncology, Vol 13, Iss 9, Pp 100791- (2020)
Epidermal growth factor receptor (EGFR) exon 19 deletion (E19del) is the most common activating mutation in advanced non–small cell lung cancer (NSCLC) and associates with the sensitivity of EGFR tyrosine kinase inhibitors (TKIs) treatment. However
Externí odkaz:
https://doaj.org/article/9fe5da973a6c44378c93ffab8bef4d4b
Autor:
Dong Chen, Xing-liang Li, Biao Wu, Xiao-bin Zheng, Wen-xian Wang, Hua-fei Chen, Yi-yu Dong, Chun-wei Xu, Mei-yu Fang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Introduction: Oncogenic mutations in the epidermal growth factor receptor (EGFR) occur frequently in patients with lung cancer. These mutations may serve as critical predictive biomarkers in patients with non-small cell lung cancer (NSCLC). Among the
Externí odkaz:
https://doaj.org/article/fc4d846b0f4b4182aeba9c4455ceadd0
Publikováno v:
Biology Open, Vol 9, Iss 1 (2020)
In clinical practice, some breast cancer (BC) patients carry a rare ERBB2 in-frame insertion (p. Pro780_Tyr781insGlySerPro) and are resistant to anti-ERBB2 therapy. To explore the potential procarcinogenic role of this ERBB2 mutation, we conducted th
Externí odkaz:
https://doaj.org/article/edffa9dcdd6e42f7b921f52a3d30fccf